Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barry George

Cardiovascular Disease Mount Vernon, OH Medical Doctor

NPI 1386605319 CMS profile 943567

1330 Coshocton Ave, Mount Vernon, OH 43050

Open in the dashboard

General payments

$5,620

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Barry George of Mount Vernon, OH is reported in the CMS Open Payments database as having received $5,620 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $524 21
2024 General $663 34
2023 General $950 51
2022 General $661 36
2021 General $478 16
2020 General $1,435 17
2019 General $910 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barry George
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Barry George were reported at $524. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Barry George Cardiovascular Disease median Middle half National median
2019 $910 $450 $127–$1,392 $163
2020 $1,435 $242 $77–$751 $114
2021 $478 $335 $101–$1,037 $132
2022 $661 $395 $121–$1,211 $149
2023 $950 $443 $136–$1,283 $160
2024 $663 $450 $136–$1,323 $164
2025 $524 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,858 84 payments
  2. Endologix, Inc. $607 4 payments
  3. Novartis Pharmaceuticals Corporation $339 20 payments
  4. Amgen Inc. $315 18 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $261 21 payments
  6. Janssen Pharmaceuticals, Inc $166 11 payments
  7. Biotronik Inc. $136 9 payments
  8. Medtronic, Inc. $134 4 payments
  9. Amarin Pharma Inc. $114 7 payments
  10. Boston Scientific Corporation $103 4 payments
  11. Other $587 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,554 204 payments
  2. Travel and Lodging $1,050 4 payments
  3. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. Allure CRT Pacemaker $1,076 7 payments
  2. AFX $467 2 payments
  3. ESPRIT $369 15 payments
  4. JETI $363 18 payments
  5. Repatha $263 15 payments
  6. LifeVest $261 21 payments
  7. LEQVIO $223 12 payments
  8. ENTRESTO $223 12 payments
  9. Supera peripheral stent system $215 3 payments
  10. XACT $204 7 payments
  11. Other $2,530 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$77,738

Medicare's payments for the services billed

Medicare patients

340

Average age 77

Services billed

770

147 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 72%
Arthritis 52%
Heart failure 50%
Atrial fibrillation 46%
Diabetes 44%
Chronic kidney disease 41%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $118
$118 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $51
$51 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $51
$51 — —
Wegovy
  • Novo Nordisk Inc $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record